


Overview: Taithera, Inc. is the first orthopaedic-focused therapeutic company. It is developing its novel, proprietary bone targeted drug delivery platform initially for the treatment of musculoskeletal disorders. The Taithera platform works via a high affinity osteoclast binding peptide functionalized nanoparticle encapsulated with a therapeutic agent.

Lead Indication: Taithera’s lead product is designed to promote fracture healing & bone formation in non-union & delayed union fractures. Of the 15 million fractures that are treated annually in the US, 15% are delayed or non-union. This segment of the fracture market represents an unmet medical need because there are no currently available safe and effective treatments. Taithera believes that its lead product will provide great benefit to an underserved patient population and generate estimated annual sales in excess of \$1BN at peak.

TBP-NP-Drug Demonstrates Robust Therapeutic Efficacy



Pipeline

Description	Taithera Pipeline						
	Proof-of-Concept	Pre-Clinical	IND Ready	Phase 1	Phase 2	Phase 3	NDA Filed
Fracture Treatment: TAI 39 (TBP-NP-Anabolic Agent)		→					
Bone Grafts: TAI 39 (TBP-NP-Anabolic Agent)	→						
Osteoporosis Treatment: TAI 1412 (TBP-NP-Anabolic Agent)		→					
Osteosarcoma Treatment: TAI 1125 (TBP-NP-Doxorubicin)	→						
Nucleic Acid Delivery: TAI 220 (TBP-NP-NA)	→						

Management Team: Seth Harlem, CEO – a seasoned, serial entrepreneur who has brought several early stage companies & products to market. Seth also established the U.S. presence of a large (\$3+BN market cap) Chinese financial technology company.

Mo Chen, PhD, CSO - a bone & tissue engineer who was most recently a Research Scientist at Columbia University Medical Center’s Craniofacial Tissue Regeneration Lab. Dr. Chen received his PhD from the University of Rochester, where he worked closely with the inventors of Taithera’s technology.

Seth and Dr. Chen both received MBAs at Columbia Business School.

Milestones:

- All Rochester R&D to date has been funded by grants from NIH and NSF
- Formulation, nanoparticle encapsulation, *in vitro* studies, *in vivo* studies, & cytotoxicity tests
- Patent filed & commercial rights secured
- **Demonstrated robust pre-clinical efficacy**

Fundraising: Currently raising \$1M on a convertible note for key milestones. Proceeds will be used to optimize the drug payload, design the shipping & handling protocol & provide the PK/PD necessary to determine the dosage in clinical trials. Oncology program will also be initiated.

Scientific Advisory Board: Dr. Edward Puzas, PhD (inventor, bone biologist), Dr. Danielle Benoit, PhD (inventor, biomedical engineer), Dr. Bing-Shiou Yang, PhD (chemical engineer, 15+ years in pharmaceutical product manufacturing), Dr. Richard Yoon, MD (orthopaedic surgeon), Dr. James Toussaint, MD (orthopaedic surgeon).

Contact: Seth Harlem, CEO email: seth.harlem@taithera.com, phone: 347.404.4408